164 related articles for article (PubMed ID: 18622681)
21. Evaluation of the pharmacokinetics of linezolid in an obese Japanese patient.
Tsuji Y; Hiraki Y; Matsumoto K; Mizoguchi A; Sadoh S; Kobayashi T; Sakamoto S; Morita K; Yukawa E; Kamimura H; Karube Y
Scand J Infect Dis; 2012 Aug; 44(8):626-9. PubMed ID: 22263918
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and pharmacodynamics of linezolid in children with cystic fibrosis.
Santos RP; Prestidge CB; Brown ME; Urbancyzk B; Murphey DK; Salvatore CM; Jafri HS; McCracken GH; Ahmad N; Sanchez PJ; Siegel JD
Pediatr Pulmonol; 2009 Feb; 44(2):148-54. PubMed ID: 19137597
[TBL] [Abstract][Full Text] [Related]
23. Linezolid for tympanostomy tube otorrhea caused by methicillin-resistant Staphylococcus aureus and multiple drug-resistant Streptococcus pneumoniae.
Isaacson G; Aronoff SC
Int J Pediatr Otorhinolaryngol; 2008 May; 72(5):647-51. PubMed ID: 18321598
[TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetic analysis of linezolid in low body weight patients with renal dysfunction.
Tsuji Y; Yukawa E; Hiraki Y; Matsumoto K; Mizoguchi A; Morita K; Kamimura H; Karube Y; To H
J Clin Pharmacol; 2013 Sep; 53(9):967-73. PubMed ID: 23918457
[TBL] [Abstract][Full Text] [Related]
25. Linezolid dosage in pediatric patients based on pharmacokinetics and pharmacodynamics.
Matsumoto K; Shigemi A; Takeshita A; Watanabe E; Yokoyama Y; Ikawa K; Morikawa N; Takeda Y
J Infect Chemother; 2015 Jan; 21(1):70-3. PubMed ID: 25305808
[TBL] [Abstract][Full Text] [Related]
26. [A case of pacemaker-lead infection by linezolid-resistant methicillin-resistant Staphylococcus aureus in a hemodialysis patient].
Kojiro M; Tsuchihashi Y; Ishida M; Furumoto A; Matsuda J; Yanagihara K; Morimoto K; Ariyoshi K
Kansenshogaku Zasshi; 2012 Nov; 86(6):778-83. PubMed ID: 23367855
[TBL] [Abstract][Full Text] [Related]
27. Linezolid pharmacokinetics in adult patients with cystic fibrosis.
Bosso JA; Flume PA; Gray SL
Antimicrob Agents Chemother; 2004 Jan; 48(1):281-4. PubMed ID: 14693551
[TBL] [Abstract][Full Text] [Related]
28. [Shifts in minimum inhibitory concentration of linezolid to Stapylococcus aureus strains isolated from 2007 to 2009].
Nakai T; Itoyama S; Kobayashi T; Hashimoto N; Kimura S
Kansenshogaku Zasshi; 2011 Jul; 85(4):386-8. PubMed ID: 21861445
[No Abstract] [Full Text] [Related]
29. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program.
Meagher AK; Forrest A; Rayner CR; Birmingham MC; Schentag JJ
Antimicrob Agents Chemother; 2003 Feb; 47(2):548-53. PubMed ID: 12543657
[TBL] [Abstract][Full Text] [Related]
30. Linezolid clearance during continuous venovenous hemodiafiltration: a case report.
Kraft MD; Pasko DA; DePestel DD; Ellis JJ; Peloquin CA; Mueller BA
Pharmacotherapy; 2003 Aug; 23(8):1071-5. PubMed ID: 12921253
[TBL] [Abstract][Full Text] [Related]
31. In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus.
Jacqueline C; Navas D; Batard E; Miegeville AF; Le Mabecque V; Kergueris MF; Bugnon D; Potel G; Caillon J
Antimicrob Agents Chemother; 2005 Jan; 49(1):45-51. PubMed ID: 15616274
[TBL] [Abstract][Full Text] [Related]
32. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections.
Weigelt J; Itani K; Stevens D; Lau W; Dryden M; Knirsch C;
Antimicrob Agents Chemother; 2005 Jun; 49(6):2260-6. PubMed ID: 15917519
[TBL] [Abstract][Full Text] [Related]
33. Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil.
Kuti JL; Kiffer CR; Mendes CM; Nicolau DP
Clin Microbiol Infect; 2008 Feb; 14(2):116-23. PubMed ID: 18076672
[TBL] [Abstract][Full Text] [Related]
34. Successful treatment of meningoencephalitis caused by methicillin-resistant Staphylococcus aureus with intravenous linezolid in an allogeneic cord blood stem cell transplant recipient.
Higa T; Tasaka T; Kubo Y; Nakagiri I; Sano F; Matsuhashi Y; Fukai Y; Wada H; Tohyama K; Sugihara T
Scand J Infect Dis; 2008; 40(11-12):990-2. PubMed ID: 18651266
[TBL] [Abstract][Full Text] [Related]
35. [Pharmacokinetic evaluation of linezolid in patients with major thermal injuries].
Le Floch R; Arnould JF; Vinsonneau C; Hovsepian L; Stephanazzi J; Bret P; Birraux G; Lovering AM
Pathol Biol (Paris); 2010 Apr; 58(2):e27-31. PubMed ID: 19854590
[TBL] [Abstract][Full Text] [Related]
36. Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections.
Stein GE; Schooley S; Peloquin CA; Missavage A; Havlichek DH
J Antimicrob Chemother; 2007 Oct; 60(4):819-23. PubMed ID: 17673476
[TBL] [Abstract][Full Text] [Related]
37. Correlation between serum linezolid concentration and the development of thrombocytopenia.
Hiraki Y; Tsuji Y; Hiraike M; Misumi N; Matsumoto K; Morita K; Kamimura H; Karube Y
Scand J Infect Dis; 2012 Jan; 44(1):60-4. PubMed ID: 21899392
[TBL] [Abstract][Full Text] [Related]
38. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA).
Itani KM; Weigelt J; Li JZ; Duttagupta S
Int J Antimicrob Agents; 2005 Dec; 26(6):442-8. PubMed ID: 16289514
[TBL] [Abstract][Full Text] [Related]
39. A reduced linezolid dosage maintains favorable efficacy with minimal hematologic toxicity in a methicillin-resistant Staphylococcus aureus-infected patient with renal insufficiency.
Taguchi K; Miyakawa T; Ohmura T; Horio M; Anraku Y; Okada T; Mizuta H; Saito H; Kawaguchi T
Scand J Infect Dis; 2013 Jan; 45(1):77-80. PubMed ID: 22992056
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and penetration of linezolid into inflamed soft tissue in diabetic foot infections.
Majcher-Peszynska J; Haase G; Sass M; Mundkowski R; Pietsch A; Klammt S; Schareck W; Drewelow B
Eur J Clin Pharmacol; 2008 Nov; 64(11):1093-100. PubMed ID: 18654767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
